Welcome to DrugCVar
Targeted therapy for cancer-related genetic variants is critical for precision medicine. Although several databases including CIViC, OncoKB, CGI, MCG provide clinical interpretations of variants in cancer, the clinical evidences were limited and miscellaneous.
In our study, we provide the DrugCVar software, which integrated our manually curated cancer variant-drug targeting evidences from literature and the interpretations from the public resources. In total, more than 7,000 clinical evidences for cancer variant-drug targeting were integrated and classified into nine evidence tiers referring to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
DrugCVar provided a comprehensive annotation tool to interpret potential drug for cancer variants especially the massive ones from clinical cancer genomics studies.